PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2010; 5(4): e10169.
Published online 2010 April 14. doi:  10.1371/journal.pone.0010169
PMCID: PMC2854688

Molecular Basis of eRF3 Recognition by the MLLE Domain of Poly(A)-Binding Protein

Petri Kursula, Editor

Abstract

PABPC1 (cytosolic poly(A)-binding protein 1) is an RNA-binding protein that binds to the poly(A) tail of mRNAs to promote translation and mRNA turnover. In addition to RNA-binding domains, PABPC1 contains a unique protein-protein interaction domain, MLLE (also known as PABC) that binds regulatory proteins and translation factors that contain a conserved 12 amino acid peptide motif termed PAM2. Eukaryotic Release Factor 3 (eRF3/GSPT1) contains two overlapping PAM2 sequences, which are required for its activity. Here, we determined the crystal structures of the MLLE domain from PABPC1 in complex with the two PAM2 regions of eRF3. The structures reveal a mechanism of cooperativity between the two PAM2 sites that increases the binding affinity but prevents the binding of more than one molecule of eRF3 to PABPC1. Relative to previous structures, the high-resolution crystal structures force a re-evaluation of the PAM2 motif and improve our understanding of the molecular basis of MLLE peptide recognition.

Introduction

In order to rapidly respond to growth and proliferation stimuli, stress, and nutrient availability, cells use translational control as an important mechanism of gene expression. Cytoplasmic poly(A)-binding protein (PABP), also termed PABPC or PABPC1, is an essential protein that binds to and mediates the stimulatory effect of the poly(A) tail on translation initiation [1]. PABPC1 contains four N-terminal phylogenetically conserved RNA recognition motifs (RRMs) while the proline-rich, C-terminal third of the protein contains an unstructured, poorly conserved region, which harbors some protein-interaction sites [2], [3], [4], [5], [6], and a well-conserved, approximately 70-residue MLLE (Mademoiselle) domain, also known as PABC [7]. The MLLE domain is also found in UBR5 (or EDD), a ubiquitin-ligase [8].

Solution and crystal structures of MLLE domains from various PABPs and human UBR5 have shown that these domains consist of a bundle of 4 or 5 α-helices [7], [8], [9], [10], [11]. Previous studies showed that MLLE is a peptide-binding domain that specifically recognizes a conserved PAM2 (for PABP-interacting motif 2) sequence [12]. This PAM2 motif was initially identified in Paip1 (PABP-interacting protein 1), Paip2 and eukaryotic Release Factor 3 (eRF3) [7]. Recent crystal structures of the MLLE domain from human PABPC1 in complex with peptides from Paip2 and Ataxin-2 reveal how the most conserved elements of PAM2 motifs bind to the helices α2, α3 and α5 of MLLE but do not reveal the full range of intermolecular interactions [13], [14].

Eukaryotic release factor eRF3, also known as G1 to S phase transition protein GSPT, is a GTPase that facilitates the nascent peptide chain release from the terminating ribosome [15], [16], [17], [18], [19]. Two genes are known: eRF3a/GSPT1 and eRF3b/GSPT2 [20]. Structurally, both consists of a C-terminal GTPase domain, homologous to elongation factor EF1A, and an N-terminal region that contains the binding site for PABPC1 [21], [22], [23]. Unlike other PAM2-containing proteins, eRF3 possesses two overlapping PAM2 sequences (PAM2-N and PAM2-C), which each independently bind to the MLLE domain of PABPC1 with low micromolar affinity [12]. This makes them the most unusual PAM2 motifs in the family. The C-terminal site (PAM2-C), in particular, lacks a leucine recognition element that is found in essentially all other PAM2 peptides. As a pair, the two PAM2 sites bind to MLLE together with enhanced affinity and are responsible for essentially all of the free energy of binding between the intact proteins, eRF3 and PABPC1 [24].

Here, we determined two crystal structures of the MLLE domain of human PABPC1 in complex with the PAM2-N and PAM2-C peptides from human eRF3. The structures reveal a shared binding element, Phe76, that contributes to binding as part of both PAM2-N and PAM-C. The commonality between the two binding sites explains the observations that the apparent loss of a single PAM2 motif is sufficient to block eRF3 binding to PABPC1 [24], [25]. Compared to previous low resolution NMR studies, the high-resolution crystal structures reveal an enlarged lexicon of peptide recognition by the MLLE domain of PABPC1 and provide an example of binding site duplication as a means of enhancing affinity.

Results

Structure of the MLLE/eRF3-PAM2 complexes

In order to understand eRF3 binding by PABPC1, we crystallized the PABPC1 MLLE domain in complex with two peptides from the N-terminal portion of eRF3 that had previously been shown to mediate PABPC1 binding. We obtained well-diffracting co-crystals with eRF3 residues 67–81 (PAM2-N) and 76–90 (PAM2-C). Both crystals displayed very low solvent content resulting from tight packing. Diffraction datasets for both complexes were solved by molecular replacement and refined to 2.3 Å for PAM2-N and 1.4 Å for PAM2-C (Table 1; PDB codes 3KUI and 3KUJ).

Table 1
Data collection and refinement statistics.

Overlay of the MLLE/PAM2-N and MLLE/PAM2-C structures reveals striking similarity of the bound conformations despite the highly divergent peptide sequences (Fig. 1). In both structures, the peptide binds by wrapping around the highly conserved KITGMLLE signature motif of MLLE and interacting with the hydrophobic pockets between helices α2 and α3 and between helices α3 and α5 of MLLE. The peptides adopt an extended conformation interrupted by a β-turn at residues Asn70-Val71-Asn72 in PAM2-N and at residues Asn79-Val80-His81 in PAM2-C (Fig. 2).

Figure 1
Overlapping PAM2 motifs of eRF3.
Figure 2
Crystal structures of the MLLE/eRF3-PAM2 complexes.

The MLLE/PAM2 interactions are mostly hydrophobic with as many as five conserved recognition elements. In the N-terminal part of the peptide, the side chain of eRF3 Leu69 of PAM2-N inserts into a hydrophobic pocket formed by the side chains of Met584, Ile588, Ala610 and the aliphatic parts of Lys606 and Glu609 (Fig. 2B). This same pocket is occupied by Phe76 and Pro78 in the PAM2-C structure (Fig. 2 E). At the tip of the peptide β-turn, the side chain of Val71/Val80 makes an additional hydrophobic contact with the MLLE side chains of Val613 and His617. Another hydrophobic interaction involves the invariantly conserved alanine at residue 73 of PAM2-N and at 82 of PAM2-C. At the C-terminus of both peptides, Phe76/Phe85 fits into the shallow cavity formed by Gly563, the methyl groups of Thr582 and Leu586 and the aliphatic part of Glu564 (Fig. 2C, 2F). Mutagenesis studies with Paip2 have shown that this is the single most important determinant of binding [12]. In addition to its essential side chain, the amide of Phe76/Phe85 hydrogen bonds with the carbonyl of Gly579. This close approach of the two backbones is reflected in the perfect conservation of this glycine in the KITGMLLE motif.

The most significant differences between the two peptide complexes occur at the N-terminus where PAM2-C lacks a highly conserved leucine residue. Mutagenesis of this residue in the PAM2 motif of Paip2 led to a loss of three orders of magnitude of binding affinity [12]. In its place, Phe76 bends back to partly occupy the space vacated by the missing leucine side chain. Thus eRF3 Phe76 plays two distinct roles in the complexes, alternately occupying the hydrophobic pocket between MLLE helices α2 and α3 in the PAM2-N complex and between helices α3 and α5 in the PAM2-C complex (Fig. 1B). The simultaneous requirement for Phe76 for MLLE binding by both PAM2-N and PAM2-C explains the previous observations of a one-to-one stoichiometry of eRF3 binding to PABPC1 despite the existence of two PAM2 motifs [24], [26].

Sequence conservation in PAM2 motifs

The high resolution structures of the peptides bound to the PABPC1 MLLE domain allows a re-evaluation of the definition of the PAM2 motif and the residues that are most essential for binding [13], [14]. We had previously described the motif as comprising 12 residues with a highly conserved leucine residue at position 3, alanine at position 7 and phenylalanine at position 10 [7], [12]. In light of the eRF3 structures, the refined definition is --Φ-(P/V)-A--F-P, where Φ, at position 3, is a hydrophobic residue, usually leucine but occasionally proline or phenylalanine (Fig. 1A). Positions 1 and 2 are normally occupied by polar or charged residues, which do not participate in MLLE binding except in the MLLE/PAM2-C structure where phenylalanine in position 1 binds in combination with proline at position 3. Position 4 is a polar residue, usually asparagine or less often serine, whose side chain makes an intermolecular ionic contact with Glu587 (the “E” in MLLE) and also stabilizes the β-turn via a hydrogen bond with the amide of residue at position 6 (Fig. 2B and 2E). The side chain of proline, valine or occasionally threonine in position 5 fits snugly into a small hydrophobic cavity in helix α5 of MLLE. The common occurrence of proline in this position may due to its propensity to form β-turns. Its mutagenesis to alanine decreased the affinity of the PAM2 motif of Paip2 by 5-fold [12]. While positions 6 and 8 are solvent-exposed and do not to contribute to MLLE binding, position 7 is invariantly alanine and binds to the methionine of the MLLE signature motif. Glutamic acid is preferred at position 9 and makes hydrogen bonds with amides of Gly579 and Lys580 in the PAM2-C structure via ordered water molecules (Fig. 2F). As previously noted, position 10 is invariantly phenylalanine and the single most important residue for binding. While position 11 is not conserved, position 12 is usually occupied by proline, which makes an addition contact with MLLE domain (Fig. 2C and 2E). While there is no sequence conservation beyond position 12, the MLLE-binding region extends by at least one more residue, as the backbone amide at position 13 makes a hydrogen bond with the side chain of conserved Glu564 of MLLE. Interestingly, most intermolecular polar contacts involve the backbone of the PAM2 peptide and do not directly affect side chain specificity.

Discussion

eRF3 is the only known protein with two high affinity PAM2 sites and the only example of overlapping sites. What is the function of the juxtaposed sites? Previous studies showed that peptides containing the individual PAM2 sites display moderate binding affinities (Kd of 3.9 and 3.1 µM) while the peptide containing the overlapping site shows a three-fold increase in binding affinity (1.3 µM) [12]. This is 1.3 times higher than the value calculated for two independent sites, based on the law of mass action, and reflects a small degree of cooperativity between the sites. In agreement with this, NMR titrations showed a large amount of conformational exchange occurs between the two sites, presumably as the MLLE domain slides along the eRF3 peptide binding alternately to PAM2-N and PAM2-C [12]. One important distinction is that the eRF3-PABPC1 complex exists exclusively in one-to-one stoichiometry as Phe76 binding is essential for both complexes (Fig. 1B). Thus the addition of a second, overlapping PAM2 site acts to augment the affinity of the eRF3-PABPC1 interaction without changing the stoichiometry of the interaction. The second site also provides redundancy and reduces the frequency of loss of binding due to a mutation in one of the PAM2 sites.

Intriguingly, this redundancy and higher affinity is lost in a fraction of eRF3 in cells that is proteolytically cleaved in the middle of PAM2-N site leaving Ala73 as the N-terminal residue [27]. This cleavage product retains an intact PAM2-C site and, based on our crystal structure and previous peptide affinity measurements, would be expected to interact with PABPC1 with 3-fold lower affinity. The protease responsible for the cleavage of eRF3 is not known but the cleavage is thought to be a regulatory mechanism to regulate eRF3 levels/localization and potentiates apoptosis by liberating caspases from inhibitors of apoptosis (IAPs) that bind to the cleaved form of eRF3.

The eRF3-PABPC1 interaction is central to eRF3′s function in regulating mRNA deadenylation [26]. Through the MLLE domain, PABPC1 interacts with two mRNA deadenylation systems, PAN2-PAN3 and Ccr4-Not-Caf1, and contributes to deadenylation of cytosolic mRNAs (Fig. 3). In both systems, binding occurs through a linker protein, PAN3 or Tob, that contains a PAM2 motif [28], [29], [30], [31]. These deadenylase complexes compete with eRF3 for binding to the MLLE domain so that their recruitment to the mRNA is regulated by eRF3 [26]. Peptide binding studies show that the overlapped PAM2 motifs of eRF3 binding with significantly (up to 30 fold) higher affinity than the PAM2 motifs of PAN3 and Tob [12], [28], [32]. Comparison of the PAM2 motifs of PAN3 and eRF3 highlights the importance of the N-terminal residues (Fig. 1A). While PAN3 does have a proline residue at position 3, it lacks the phenylalanine residue at position 1 that binds to the MLLE hydrophobic pocket between helices α3 and α5.

Figure 3
Model of PABPC1 interacting with proteins in translation termination and deadenylation.

Binding studies with the full-length proteins PABPC1 and eRF3 have reported affinities very similar to those measured for MLLE binding the overlapping PAM2 site [24]. Thus, it appears that the PAM2 motifs of eRF3 are the only interaction sites for binding to PABPC1. This is supported by mutagenesis studies. Recently, a four residue mutant of eRF3 (L69K, N72A, A73K, F76A) was shown to have a compromised binding to PABPC1 [25]. Similarly, mutagenesis of the PAM2-C sequence (H81A, A82K, F85A) was shown to block eRF3 binding to PABPC1 as measured by isothermal titration calorimetry [24]. These are consistent with studies of other PAM2-containing proteins, which have shown that the phenylalanine residue at position 10 is required for binding and function. Specifically, mutagenesis of PAN3 (F93A) [28], Tob (F274A) [26] and NFX1-123 (F20A) [33] were all shown to disrupt binding to PABPC1 in cells.

In summary, the high-resolution X-ray crystal structures presented here significantly improve our understanding of the eRF3-PABPC1 interactions and, in general, PAM2 recognition by the MLLE domain of PABPC1. Despite significant sequence divergence, the two PAM2 peptides of eRF3 bind with almost identical conformations and show synergy when combined as an overlapped pair of binding sites. The refined definition of the PAM2 motif strongly suggests that other more divergent PAM2-containing proteins, such as PAN3 and Tob, will interact with PABPC1 in a manner very similar to the eRF3 PAM2 motifs.

Materials and Methods

MLLE expression, purification and peptide synthesis

The MLLE domain (residues 544–626) of human PABPC1 was cloned into pGEX-6P-1 vector (Amersham-Pharmacia) and expressed and purified as described previously for the longer 544–636 fragment [12] with the addition of a final size-exclusion chromatography step.

The PAM2 peptides were synthesized by Fmoc solid-phase peptide synthesis and purified by reverse phase chromatography on a C18 column (Vydac, Hesperia, CA). The composition and purity of the peptides was verified by ion-spray quadruple mass spectroscopy.

Crystallization

Crystallization conditions for the MLLE domain in complex with the PAM2 peptides from eRF3 were identified utilizing hanging drop vapor diffusion with the AmSO4 crystallization suite (QIAGEN). The best MLLE/PAM2-N crystals were obtained by equilibrating a 1 µl drop of PABPC1 (544–626)/eRF3 (67–81) mixture (10 mg/ml) in 1[ratio]2 molar ratio in a buffer (10 mM MES, 100 mM NaCl, pH 6.3), mixed with 1 µl of reservoir solution containing 2.1 M ammonium sulfate, 0.2 M sodium sulfate, 10 mM zinc chloride and 0.1 M sodium acetate at pH 5.4. Crystals grew in 10–20 days at 22°C. The solution for cryoprotection contained the reservoir solution with the addition of 15% (v/v) glycerol. The crystals contain one MLLE and one PAM2-N molecule in the asymmetric unit corresponding to Vm = 1.7 Å3 Da−1 and a solvent content of 28.5%. The best MLLE/PAM2-C crystals were obtained by equilibrating a 1 µl drop of PABPC1 (544–626)/eRF3 (76–90) mixture (10 mg/ml) in 1[ratio]2 molar ratio in a buffer (10 mM MES, 100 mM NaCl, pH 6.3), mixed with 1 µl of reservoir solution containing 1.4 M ammonium sulfate and 0.1 M citric acid pH 4.0. Crystals grew in 5–10 days at 22°C. The solution for cryoprotection contained the reservoir solution with the addition of 20% (v/v) glycerol. The crystals contain one MLLE and one PAM2-C molecule in the asymmetric unit corresponding to Vm = 1.7 Å3 Da−1 and a solvent content of 26.1% [34].

Structure solution and refinement

Diffraction data from a single crystal of the MLLE/PAM2-C complex were collected on an ADSC Quantum-210 CCD detector (Area Detector Systems Corp.) at beamline F2 at the Cornell High-Energy Synchrotron Source (CHESS) (Table 1). Diffraction data from a single crystal of the MLLE/PAM2-N complex were collected on a Rigaku R-Axis IV++ imaging-plate detector at the McGill Macromolecular X-ray Diffraction Facility. Data processing and scaling were performed with HKL2000 [35]. The structures were determined by molecular replacement with Phaser [36], using the coordinates of unliganded MLLE from human EDD (PDB entry 1I2T). The initial MLLE/PAM2-C model obtained from Phaser was completed and adjusted with the program Coot [37] and improved by several cycles of refinement, using the program REFMAC 5.2 [38] and model refitting. At the latest stage of refinement, we also applied the translation-libration-screw (TLS) option [39] with final density for PABPC1 residues 544–620 and eRF3 residues 76–90. The MLLE/PAM2-N model was refined using CNS [40] with density for PABPC1 residues 545–625 and eRF3 residues 67–80. The models have good stereochemistry according to the program PROCHECK [41] (Table 1) and well-defined density for the bound peptide (Supplemental Figure S1).

Supporting Information

Figure S1

Electron density from the eRF3 PAM2-N (A) and PAM2-C (B) peptides contoured at 1 σ from the 2FO-FC omit maps. The PAM2-N (yellow) and PAM2-C (magenta) peptides are shown in stick representation and the MLLE domain is shown in cartoon representation (green).

(0.15 MB PDF)

Acknowledgments

We acknowledge data acquisition at the Macromolecular Diffraction (MacCHESS) facility at the Cornell High Energy Synchrotron Source (CHESS), which is supported by the National Science Foundation and the National Institutes of Health. The coordinates and structure factors have been deposited in the RCSB Protein Data Bank under codes 3KUI and 3KUJ.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This study was funded by the Canadian Institutes of Health Research grant MOP-14219. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Mangus DA, Evans MC, Jacobson A. Poly(A)-binding proteins: multifunctional scaffolds for the post-transcriptional control of gene expression. Genome Biol. 2003;4:223. [PMC free article] [PubMed]
2. Kuhn U, Pieler T. Xenopus poly(A) binding protein: functional domains in RNA binding and protein-protein interaction. J Mol Biol. 1996;256:20–30. [PubMed]
3. Gray NK, Coller JM, Dickson KS, Wickens M. Multiple portions of poly(A)-binding protein stimulate translation in vivo. EMBO J. 2000;19:4723–4733. [PubMed]
4. Collier B, Gorgoni B, Loveridge C, Cooke HJ, Gray NK. The DAZL family proteins are PABP-binding proteins that regulate translation in germ cells. Embo J. 2005;24:2656–2666. [PubMed]
5. Mangus DA, Evans MC, Agrin NS, Smith M, Gongidi P, et al. Positive and negative regulation of poly(A) nuclease. Mol Cell Biol. 2004;24:5521–5533. [PMC free article] [PubMed]
6. Patel GP, Bag J. IMP1 interacts with poly(A)-binding protein (PABP) and the autoregulatory translational control element of PABP-mRNA through the KH III-IV domain. FEBS J. 2006;273:5678–5690. [PubMed]
7. Kozlov G, Trempe JF, Khaleghpour K, Kahvejian A, Ekiel I, et al. Structure and function of the C-terminal PABC domain of human poly(A)- binding protein. Proc Natl Acad Sci U S A. 2001;98:4409–4413. [PubMed]
8. Deo RC, Sonenberg N, Burley SK. X-ray structure of the human hyperplastic discs protein: an ortholog of the C-terminal domain of poly(A)-binding protein. Proc Natl Acad Sci U S A. 2001;98:4414–4419. [PubMed]
9. Kozlov G, Siddiqui N, Coillet-Matillon S, Trempe JF, Ekiel I, et al. Solution structure of the orphan PABC domain from Saccharomyces cerevisiae poly(A)-binding protein. J Biol Chem. 2002;277:22822–22828. [PubMed]
10. Siddiqui N, Osborne MJ, Gallie DR, Gehring K. Solution structure of the PABC domain from wheat poly (A)-binding protein: an insight into RNA metabolic and translational control in plants. Biochemistry. 2007;46:4221–4231. [PubMed]
11. Siddiqui N, Kozlov G, D'Orso I, Trempe JF, Gehring K. Solution structure of the C-terminal domain from poly(A)-binding protein in Trypanosoma cruzi: a vegetal PABC domain. Protein Sci. 2003;12:1925–1933. [PubMed]
12. Kozlov G, De Crescenzo G, Lim NS, Siddiqui N, Fantus D, et al. Structural basis of ligand recognition by PABC, a highly specific peptide-binding domain found in poly(A)-binding protein and a HECT ubiquitin ligase. EMBO J. 2004;23:272–281. [PubMed]
13. Kozlov G, Safaee N, Rosenauer A, Gehring K. Structural basis of binding of P-body associated proteins GW182 and Ataxin-2 by the Mlle domain of poly(A)-binding protein. J Biol Chem. 2010;285 [PMC free article] [PubMed]
14. Kozlov G, Menade M, Rosenauer A, Nguyen L, Gehring K. Molecular determinants of PAM2 recognition by the MLLE domain of poly(A)-binding protein. J Mol Biol. 2010;397:397–407. [PubMed]
15. Zhouravleva G, Frolova L, Le Goff X, Le Guellec R, Inge-Vechtomov S, et al. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J. 1995;14:4065–4072. [PubMed]
16. Hauryliuk V, Zavialov A, Kisselev L, Ehrenberg M. Class-1 release factor eRF1 promotes GTP binding by class-2 release factor eRF3. Biochimie. 2006;88:747–757. [PubMed]
17. Kononenko AV, Mitkevich VA, Dubovaya VI, Kolosov PM, Makarov AA, et al. Role of the individual domains of translation termination factor eRF1 in GTP binding to eRF3. Proteins. 2008;70:388–393. [PubMed]
18. Mitkevich VA, Kononenko AV, Petrushanko IY, Yanvarev DV, Makarov AA, et al. Termination of translation in eukaryotes is mediated by the quaternary eRF1*eRF3*GTP*Mg2+ complex. The biological roles of eRF3 and prokaryotic RF3 are profoundly distinct. Nucleic Acids Res. 2006;34:3947–3954. [PMC free article] [PubMed]
19. Pisareva VP, Pisarev AV, Hellen CU, Rodnina MV, Pestova TV. Kinetic analysis of interaction of eukaryotic release factor 3 with guanine nucleotides. J Biol Chem. 2006;281:40224–40235. [PubMed]
20. Hoshino S, Imai M, Mizutani M, Kikuchi Y, Hanaoka F, et al. Molecular cloning of a novel member of the eukaryotic polypeptide chain-releasing factors (eRF). Its identification as eRF3 interacting with eRF1. J Biol Chem. 1998;273:22254–22259. [PubMed]
21. Cosson B, Couturier A, Chabelskaya S, Kiktev D, Inge-Vechtomov S, et al. Poly(A)-binding protein acts in translation termination via eukaryotic release factor 3 interaction and does not influence [PSI(+)] propagation. Mol Cell Biol. 2002;22:3301–3315. [PMC free article] [PubMed]
22. Hoshino S, Imai M, Kobayashi T, Uchida N, Katada T. The eukaryotic polypeptide chain releasing factor (eRF3/GSPT) carrying the translation termination signal to the 3′-Poly(A) tail of mRNA. Direct association of erf3/GSPT with polyadenylate-binding protein. J Biol Chem. 1999;274:16677–16680. [PubMed]
23. Uchida N, Hoshino S, Imataka H, Sonenberg N, Katada T. A Novel Role of the Mammalian GSPT/eRF3 Associating with Poly(A)- binding Protein in Cap/Poly(A)-dependent Translation. J Biol Chem. 2002;277:50286–50292. [PubMed]
24. Kononenko AV, Mitkevich VA, Atkinson GC, Tenson T, Dubovaya VI, et al. GTP-dependent structural rearrangement of the eRF1:eRF3 complex and eRF3 sequence motifs essential for PABP binding. Nucleic Acids Res. 2010;38:548–558. [PMC free article] [PubMed]
25. Singh G, Rebbapragada I, Lykke-Andersen J. A competition between stimulators and antagonists of Upf complex recruitment governs human nonsense-mediated mRNA decay. PLoS Biol. 2008;6:e111. [PMC free article] [PubMed]
26. Funakoshi Y, Doi Y, Hosoda N, Uchida N, Osawa M, et al. Mechanism of mRNA deadenylation: evidence for a molecular interplay between translation termination factor eRF3 and mRNA deadenylases. Genes Dev. 2007;21:3135–3148. [PubMed]
27. Hegde R, Srinivasula SM, Datta P, Madesh M, Wassell R, et al. The polypeptide chain-releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein. J Biol Chem. 2003;278:38699–38706. [PubMed]
28. Siddiqui N, Mangus DA, Chang TC, Palermino JM, Shyu AB, et al. Poly(A) nuclease interacts with the C-terminal domain of polyadenylate-binding protein domain from poly(A)-binding protein. J Biol Chem. 2007;282:25067–25075. [PubMed]
29. Horiuchi M, Takeuchi K, Noda N, Muroya N, Suzuki T, et al. Structural basis for the antiproliferative activity of the Tob-hCaf1 complex. J Biol Chem. 2009;284:13244–13255. [PMC free article] [PubMed]
30. Simon E, Seraphin B. A specific role for the C-terminal region of the Poly(A)-binding protein in mRNA decay. Nucleic Acids Res. 2007;35:6017–6028. [PMC free article] [PubMed]
31. Ezzeddine N, Chang TC, Zhu W, Yamashita A, Chen CY, et al. Human TOB, an antiproliferative transcription factor, is a poly(A)-binding protein-dependent positive regulator of cytoplasmic mRNA deadenylation. Mol Cell Biol. 2007;27:7791–7801. [PMC free article] [PubMed]
32. Lim NS, Kozlov G, Chang TC, Groover O, Siddiqui N, et al. Comparative peptide binding studies of the PABC domains from the ubiquitin-protein isopeptide ligase HYD and poly(A)-binding protein. Implications for HYD function. J Biol Chem. 2006;281:14376–14382. [PubMed]
33. Katzenellenbogen RA, Egelkrout EM, Vliet-Gregg P, Gewin LC, Gafken PR, et al. NFX1-123 and poly(A) binding proteins synergistically augment activation of telomerase in human papillomavirus type 16 E6-expressing cells. J Virol. 2007;81:3786–3796. [PMC free article] [PubMed]
34. Matthews BW. Solvent content of protein crystals. J Mol Biol. 1968;33:491–497. [PubMed]
35. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–326.
36. Read RJ. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr. 2001;57:1373–1382. [PubMed]
37. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126–2132. [PubMed]
38. Murshudov GN, Vagin AA, Lebedev A, Wilson KS, Dodson EJ. Efficient anisotropic refinement of macromolecular structures using FFT. Acta Crystallogr D Biol Crystallogr. 1999;55:247–255. [PubMed]
39. Winn MD, Murshudov GN, Papiz MZ. Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol. 2003;374:300–321. [PubMed]
40. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr. 1998;54:905–921. [PubMed]
41. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26:283–291.

Articles from PLoS ONE are provided here courtesy of Public Library of Science